Review

LifeMD semaglutide review

$1,788 a year, all in. That is $768 more than the cheapest option. Insurance coordination.

Illustration of bottles and boxes lined up on a shelf

Recorded article date: 2026-09-18

This article retains historical comparison material. Its record date is not a current offer check. Selected newer reviews have their own dates and limits; consult those reviews and the applicable written terms before comparing a purchase.


The LifeMD programme fee is about $1,788 a year, or nearer $900 on the annual plan. Medication is separate unless your insurance covers it.

Where coverage lands, patient cost for branded semaglutide can fall to roughly $25 a month, which is the scenario the marketing is built around. Where it does not, you are paying a programme fee and full freight for the drug.

The yearly bill

Historical comparison: saved figures with their record dates. Monthly figures may be equivalents; multiplying by twelve models an unchanged input, not a confirmed annual bill. Publisher-selected placement differs from numerical order.
LifeMD · semaglutide
Advertised from$75/mo
Membership on topNone
What you actually pay$149/mo
Over twelve months$1,788
Versus the cheapest option+$768 a year
Cheapest-first position0 of 16

Same structure. The value depends on whether coverage comes through.

Where the money goes

Genuine clinician oversight — a physician-led practice rather than a questionnaire and a shipping label. That is worth something independent of the insurance question.

Physician-led telehealth group with a weight-management programme built around insurance coordination and branded prescriptions.

What the same money buys elsewhere

Coreage Rx’s twelve-month semaglutide plan is $948 including the advertised care and medication, below the annualized LifeMD fee discussed here before any medication charge. Coverage for an FDA-approved product may change the out-of-pocket result.

Historical comparison: saved figures with their record dates. Monthly figures may be equivalents; multiplying by twelve models an unchanged input, not a confirmed annual bill. Publisher-selected placement differs from numerical order.
ProgrammeRecorded monthly figureRecorded figure × 12Difference from stored minimum × 12Record date
Coreage Rx Paid first placement
Recorded membership: $0
$139$1,668+$6482026-10-04
SuperHealthy Rx Publisher-selected placement
Recorded membership: $0
$85$1,020—2026-10-04
Likeness Rx Publisher-selected placement
Recorded membership: $0
$139$1,668+$6482026-10-04
Ozari Health
Recorded membership: $0
$86$1,032+$122026-09-18
Trimi
Recorded membership: $0
$99$1,188+$1682026-09-18
Zealthy
Recorded membership: $0
$151$1,812+$7922026-09-18

Is the extra worth it?

Only with coverage. This is not a cash-pay bargain and does not really claim to be.

What we checked

  • GLP-1 injection programme listed at $75 first month, then $149/month.
  • Annual plan advertised as low as $75/month.
  • Programme fee does not include medication when medication is branded and billed to insurance.
  • Markets insurance coordination that can reduce semaglutide cost to roughly $25/month where coverage applies.

Verified 2026-09-18. Prices in this market move, so treat anything older than a month as a starting point rather than a quote.

The good

  • Genuine clinician oversight with a physician-led model.
  • Insurance work is a core part of the service, not an afterthought.
  • Annual plan meaningfully reduces the programme fee.

The bad

  • The programme fee buys care, not medication.
  • Cash-pay outcomes are far less attractive than insured ones.

Watch for this at checkout. If your insurer declines, the $149/month programme fee still applies and the medication is extra.

Verdict

Check your formulary. It is the only fact that matters for this one.

Full workings for every programme are in the cheapest semaglutide programmes, and our scoring is explained on how we rate.

Read next

CoreAge Rx pays us a commission on sign-ups through our links and pays for the first position in our price tables where included. How we rate · Disclosure